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Psoriasis is a chronic skin disease with substantial impact
on patients’ social and relational ways of living and
subsequently on their quality of life. The aim of this study
was to evaluate the health-related quality of life (HRQoL)
of patients with moderate to severe psoriasis treated with
short contact dithranol treatment, UVB phototherapy or
inpatient dithranol treatment. HRQoL was evaluated in
an open randomized multicentre study by appliance of the
Dutch short form of the Sickness Impact Profile and the
Psoriasis Disability Index; 250 patients were included.
Successful short contact dithranol treatment and UVB
phototherapy both led to a comparable improvement in
HRQoL immediately after treatment until the end of the
follow-up (maximum 1 year). Inpatients experienced a
more impaired HRQoL and showed no significant
improvement in HRQoL directly following treatment. At
the end of the study HRQoL became comparable for all
treatment groups. All three treatments led to substantial
improvement in HRQoL; however, patients treated by
short contact treatment or UVB showed a better HRQoL
than inpatients. Key words: psoriasis; health-related quality
of life; short contact dithranol treatment; inpatient
treatment; UVB phototherapy.
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Psoriasis can be treated by various topical treatments,
systemic drugs or photo(chemo)therapy. Because no
curative treatment is available yet, all interventions are
merely focused on the temporary relief of the burden of
psoriasis and improvement in health status or quality
of life (i.e. health-related quality of life, HRQoL). To
evaluate HRQoL, generally two different variants of
HRQoL instruments are available. Generic HRQoL
instruments are designed for all kinds of diseases and
medical treatments, whereas disease-specific HRQoL
instruments are designed to assess HRQoL in specific
diagnostic groups of patient populations (1).
The subjective appraisal of psoriasis seems to be
highly affected by factors such as the location of the
plaques, age, marital status and employment status (2).
Psoriasis patients report a lower HRQoL than the
general population. A prominent factor in the evalua-
tion of psoriasis is the patients’ concern about how they
are perceived and evaluated by others. To a large extent
this determines the experienced social and emotional
consequences of psoriasis (2–4). Common reactions
to psoriasis are social discomfort, embarrassment,
impaired daily activities, anxiety, anger, depression
and social isolation (5). All these reactions may be
reflected in higher scores on HRQoL instruments,
especially on the domains: social lives, family relation-
ships, leisure time and emotional well-being (3, 6, 7).
To evaluate the effect on HRQoL of three currently
available treatment modalities for moderate to severe
psoriasis (8) we performed an open randomized multi-
centre study. The study was performed alongside a
cost-effectiveness analysis concerning the same three
treatments (9, 10). The treatments under study were:
short contact dithranol treatment in a care instruction
programme (short contact treatment) at a day-care
centre, UVB phototherapy and inpatient dithranol
treatment (inpatient treatment). The main goal was
to evaluate if HRQoL was influenced in different ways
by different treatments, and to evaluate if HRQoL
measurements are suitable to use as an alternative
outcome measure besides clinical signs. Two HRQoL
instruments were applied, one generic and one
disease-specific (11, 12).
MATERIALS AND METHODS
Design
An open randomized multicentre study was designed with the
following treatments: short contact dithranol treatment in
a care instruction programme at a day-care centre, UVB
phototherapy and inpatient dithranol treatment. Two extra-
mural day-care centres and four university centres with day-
care facilities participated.
Randomization was concealed (envelopes); patients were
randomized within three parallel randomization strata over the
three treatments under study. Stratum I comprised all three
treatments. Stratum II comprised short contact treatment and
inpatient treatment, so patients with a contra-indication for
UVB phototherapy or who did not want this therapy were
randomized within this group. Patients who rejected inpatient
treatment were randomized in stratum III, containing short
contact treatment and UVB.
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Short contact dithranol treatment was performed in a
care instruction programme at a day-care centre. This
care instruction programme aims to instruct the patient to
recognize the different aspects of his/her disease and to react
adequately to it by treatment. Patients were treated and
instructed at the day-care centre twice a week, and treated
themselves at home on the other 5 days of the week. Dithranol
(0.1–5.0%) was applied in a cream and washed off after 15–
45 min. UVB phototherapy was performed three times a week.
Treatment was started with 50% of the minimal erythemal
dose (MED), and increased according to a scheme just below
erythema. During inpatient treatment dithranol (0.05–5.0%) in
petrolatum was applied diffusely for 24 h.
The Psoriasis Area and Severity Index (PASI) and the total
percentage of involved body surface (area) were used to
evaluate clinical effectiveness (13, 14). The area at the start of
treatment (baseline area) was chosen as most prominent
reference value to evaluate the treatments. This area was
defined by the ‘rule of hand’ that is also used in the PASI
score. The area of the hand of the patient stands for 1% of his/
her total body surface (13). Following successful treatment
(90% clearance of the baseline area) patients were seen
monthly until a relapse occurred (recurrence of 50% of the
baseline area), with a maximum follow-up period of 1 year.
This cut-off point for a relapse was chosen because the clinical
effect of our study treatment had largely disappeared when
50% of the baseline area had recurred. At this point patients
had to be able to get another treatment besides the local
treatments that were allowed during follow-up. This follow-up
treatment was defined in a protocol and consisted of topical
treatments only (descaling ointment, coaltar shampoo, beta-
methasone or desoximetasone lotion or emulsion, clobetasone,
fluticasone, betamethasone or clobetasol cream or ointment,
calcipotriol ointment, and petrolatum 50% in cr. Lanette I).
Therapy failure was defined asv90% clearance of the baseline
area after the maximal treatment period of 12 weeks for short
contact treatment or UVB, or after 8 weeks of inpatient
treatment. When there was no improvement of the psoriasis
during treatment, stop criteria were defined to determine if a
treatment could be classified as a therapy failure. These criteria
werev25% improvement in PASI after 2 (inpatient treatment)
or 3 (short contact treatment/UVB) weeks of treatment,v50%
improvement in PASI after 4 (inpatient treatment) or 6 (short
contact treatment/UVB) weeks of treatment. After therapy
failure the study ended.
Evaluation of HRQoL was performed at four time
points: the start of treatment, the end of treatment, 3 months’
follow-up and the end of the study. A generic and a disease-
specific instrument were applied.
Sickness Impact Profile
The Dutch short form of the Sickness Impact Profile (SIP68)
was used as the generic HRQoL instrument. The SIP68 was
developed in the Netherlands in 1994. It contains 68 items that
form 6 subscales covering aspects of health and functional
status (Table I) (15–17). Patients are asked to report on their
condition as it is on the day of collection. It takes 10 min to
answer the questions, which are in a yes-no mode (no50,
yes51). Scores range from 0 to 68, with higher scores implying
higher impairment. The SIP68 correlates well with the original
136-item version of the SIP (15), which was proven to be
appropriate in other psoriasis studies (11, 16).
Psoriasis Disability Index
The Dutch translation of the Psoriasis Disability Index (PDI)
was used as the disease-specific HRQoL instrument; the score
expresses an accumulation of psoriasis-related disability in
daily activities, at work, in personal relationships, in leisure
activities and in treatment. The PDI was the first disease-
specific HRQoL instrument developed for psoriasis patients
(18–20). The instrument was designed to measure treatment-
induced changes in disability caused by moderate to severe
psoriasis (21, 22). Unlike the Emotional Stability subscale of
the SIP-68, the PDI does not measure the emotional impact of
psoriasis. The clinical severity of psoriasis is described to be no
indication of the severity as experienced by the patient.
Consequently clinical severity hardly ever correlates with the
experienced quality of life as measured by the PDI (11, 23).
The instrument was used to reveal the relative benefit of
treatment from the patient’s view. Respondents consider the
past 4 weeks, rating questions on a 7-point linear analogue
scale (0 5 no disability, 6 5 maximum disability). An overall
index of disability is derived, representing the sum of all
answers, with scores ranging from 0 to 90. The patient’s
disability increases with the score (24).
Statistical analysis
Included in the analysis was the ‘intention to treat’ population,
consisting of all patients randomized who, after baseline
measurements, appeared at least once during treatment. At
3 months’ follow-up only patients still in remission were
analysed. Only completed HRQoL instruments were included;
no imputation methods were employed to replace missing
data. Due to the design of the study and the patients’ flow,
different numbers of patients were included at the four possible
time points of measurement. Prior to the analysis we checked
Table I. Short form of the Sickness Impact Profile, SIP68
Subscales Items Questions concerning
Somatic Autonomy (SA) 17 Someone’s basal somatic functions like dressing, eating, walking or the need for help concerning these matters
Motor Control (MC) 12 Motor functioning concerning walking, and hand and arm control
Psychological Autonomy
and Communication
(PAC)
11 If someone functions independently psychically, including verbal communication, with questions on e.g.
concentration, being confused, stuttering, and making decisions
Social Behaviour (SB) 12 Possible consequences of a disease concerning interpersonal contacts such as sexual activity, visiting friends,
and joining group activities
Emotional Stability (ES) 6 The emotional consequences of a disease with questions on irritability and irritation concerning oneself and
others
Mobility Range (MR) 10 Usual daily activities like shopping, cleaning the house and handling financial matters, and to what extent
the patients participate in these
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whether there was a statistically significant difference between
the different centres.
The PDI and SIP68 scores were transformed to a 0–100
point score to facilitate interpretation. Paired t-tests were
performed for each treatment separately, to detect statistically
significant differences in HRQoL between the four time points
of measurement. Testing for differences between the three
treatment groups was performed by ANOVA (post hoc test
for unequal variances, Dunnett’s C). Association measures
(Pearson correlation, two-tailed) were applied to determine the
relationship between the clinical severity scores (PASI, area
score) and the HRQoL measures (SIP68, PDI).
RESULTS
Overall, 250 patients were included in the study. Twelve
patients were excluded because they did not return after
the baseline assessment (short contact treatment, 7;
UVB, 4; inpatient treatment, 1). The ‘intention to treat’
group consisted of 238 patients. The patient demo-
graphics are outlined in Table II. The number of
patients and patient flow are depicted in Fig. 1. The
mean treatment duration until successful treatment was
75 days (SD 16) for short contact treatment, 72 days
(SD 17) for UVB and 37 days (SD 14) for inpatient
treatment. The relapse rate after 1 year for short contact
treatment, UVB and inpatient treatment was 38%, 58%,
and 70%, respectively. Patients successfully treated
by short contact treatment had a significantly longer
remission time than those receiving inpatient treatment.
The results (mean and SD) of the SIP68 and the PDI
are listed in Tables III and IV, respectively. At the end
of inpatient treatment the PDI showed a major
hospitalization effect. Therefore at the end of inpatient
treatment the PDI was left out of analysis, because it did
not reflect psoriasis disability, but merely disability
caused by hospitalization. Hence, as patients were
unable to carry out leisure time or social activities
during their hospital stay, they scored high on disability
regarding these items. Statistical analysis showed that
there was no influence of centre on the HRQoL scores.
The SIP68 and the PDI scores correlated well on all four
measurements (pv0.01). A correlation between the area
score and the PASI on one hand and the PDI or SIP68
scores on the other hand, was found for inpatient
treatment at 3 months’ follow-up (area/SIP68, pv0.05;
area/PDI, pv0.01; PASI/PDI, pv0.01).
Overall, patients with a therapy failure tended to
score worse than patients with a successful treatment; a
significantly deteriorated score was found for the PDI
(UVB, pv0.05; short contact treatment, pv0.001).
Fig. 2 shows the results of the scores of the SIP68 and
the PDI with the numbers of completed instruments
underneath each time point of measurement. At 3
months’ follow-up only patients still in remission were
analysed. Only completed HRQoL instruments were
included. Due to the design of the study and the
patients’ flow, different numbers of patients were
included at the four possible time points of measure-
ment. At the start of therapy all completed HRQoL
questionnaires were included, at the end of therapy only
those with a successful therapy were included, because
this was the group that was followed-up. This explains
the fall in number of patients underneath the figures.
At the end of treatment in the inpatient group the
PDI scores were left out of analysis. In general, an
improvement in the HRQoL score can be observed for
the three treatments, for the SIP68 as well as the PDI.
Short contact treatment led to a statistically signifi-
cant improvement in HRQoL (SIP68, pv0.05; PDI,
pv0.001) directly following treatment, which further
improved during the first 3 months of follow-up and
remained at an equivalent level until the end of the
study. When comparing the SIP68 subscores at the start
of treatment with those at 3 months’ follow-up, patients
experienced a significant improvement in Mobility
Range (pv0.01) and Emotional Stability (pv0.05).
UVB phototherapy gave a statistically significant
improvement in HRQoL (SIP68, pv0.05; PDI,
Table II. Demographics of patients in the ‘intention to treat’
population – mean (SD) of Psoriasis Area and Severity Index
(PASI), area of involved skin (Area%) and age, and male/
female ratio
Treatment n
Mean baseline
Mean age
M/F
ratioPASI Area%
Short contact
dithranol
100 14.1 (5.5) 19.3 (13.1) 46.1 (13.6) 67/33
UVB 78 14.6 (6.8) 20.1 (13.7) 47.1 (15.3) 53/25
Inpatient
dithranol
60 18.2 (8.4) 24.9 (14.6) 47.3 (14.4) 40/20
Overall 238 15.3 (6.9) 21.0 (13.8) 46.7 (14.3) 160/78
M, male; F, female.
Fig. 1. Flow chart for patients under study. f-u5follow-up; rem5re-
mission; SCT5short contact treatment with dithranol.
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pv0.001) directly following treatment, which remained
significant after 3 months of follow-up (SIP68, pv0.01;
PDI, pv0.001). At the end of the study the PDI
worsened significantly (pv0.05) when compared with
3 months’ follow-up. Comparing the SIP68 sub-domains
at the start of treatment with 3 months’ follow-up,
a significant improvement was observed in Social
Behaviour (pv0.01).
Inpatient treatment did not lead to a statistically
significant improvement in the SIP68 score directly
following treatment. At 3 months’ follow-up, the
improvement in HRQoL became significant (SIP68,
pv0.05; PDI, pv0.001). From 3 months’ follow-up to
the end of the study the PDI score showed a significant
worsening (pv0.001). Comparing the sub-domains of
the SIP68 from the start of treatment with 3 months’
follow-up, a significant improvement could be observed
for Social Behaviour (pv0.01).
Inpatients scored significantly worse on both HRQoL
instruments at the start of treatment compared with the
other two treatment groups; they also remained at a
relatively higher level during the study. At the end of
treatment inpatients scored significantly worse on the
SIP68 (pv0.01) compared with patients with short
contact treatment; this difference remained significant
up to 3 months’ follow-up (pv0.05). Compared with
both other treatment modalities the Social Behaviour
sub-domain of the SIP68 for inpatient treatment was
impaired more at the start and the end of treatment
(pv0.01). At the end of treatment, additionally inpa-
tient treatment scored worse in the Mobility Range
sub-domain (pv0.01) compared with short contact
treatment. At the end of the study both HRQoL scores
became comparable for the three treatment modalities,
except for the PDI score for inpatient treatment. This
was significantly worse (pv0.05) than the PDI score for
Table III. Results of the Psoriasis Disability Index (PDI) for each of the treatment modalities at the four time points of measurement
Treatment
Start of treatment
(n) mean (SD)
End of treatment
(n) mean (SD)
3 months follow-up
(n) mean (SD)
End of study
(n) mean (SD)
Therapy-failure Success
Short contact (98) 25.2 (17.6) (35) 27.7 (18.7) (58) 15.2 (10.0) (48) 7.0 (8.9) (47) 9.5 (12.0)
UVB (78) 27.7 (18.0) (30) 21.7 (17.7) (44) 11.5 (15.6) (36) 8.5 (13.8) (30) 14.0 (19.3)
Inpatient (60) 39.7 (21.7) (5)a (52)a (49) 12.4 (13.1) (39) 19.6 (16.5)
aThe PDI for inpatients at the end of treatment was left out of the analysis as noted in the Results section.
Table IV. Mean and subscores of the Sickness Impact Profile, SIP68 (SD) for each of the treatment modalities at the four
measurements, including somatic autonomy (SA), motor control (MC), psychological autonomy and communication (PAC), social
behaviour (SB), emotional stability (ES) and mobility range (MR)
Treatment Subscore/SIP Start of treatment
End of treatment
3 months
follow-up End of studyTherapy failure Successful
Short contact SA 0.3 (1.7) 0.7 (3.1) 0.1 (0.8) 0.1 (0.8) 0.3 (1.2)
MC 5.6 (13.4) 11.0 (23.6) 3.0 (9.8) 3.1 (10.0) 2.0 (8.0)
PAC 9.3 (19.7) 7.0 (16.5) 6.6 (15.3) 4.8 (11.6) 3.0 (8.5)
SB 11.3 (17.7) 16.0 (21.2) 6.4 (12.4) 5.8 (13.8) 5.3 (13.6)
ES 12.5 (24.0) 8.6 (22.6) 5.1 (12.5) 3.4 (10.2) 2.8 (10.0)
MR 3.5 (11.9) 5.4 (16.5) 0.7 (2.5) 0.4 (1.2) 0.4 (2.0)
SIP68 7.1 (11.4) 8.1 (14.3) 3.6 (6.1) 2.9 (6.0) 2.3 (5.2)
UVB SA 0.1 (0.7) 0.0 (0.0) 0.3 (1.2) 0.5 (2.2) 0.4 (1.5)
MC 5.6 (14.5) 6.1 (12.6) 4.4 (14.5) 6.7 (18.6) 8.3 (20.6)
PAC 9.4 (19.5) 7.0 (16.9) 6.0 (17.4) 7.3 (18.8) 6.7 (18.9)
SB 13.4 (20.6) 10.6(16.9) 6.8 (17.6) 6.7 (17.0) 12.2 (24.7)
ES 14.1 (23.6) 9.0 (15.8) 6.8 (17.7) 5.1 (14.8) 7.2 (19.9)
MR 3.6 (9.3) 2.3 (8.2) 1.8 (6.6) 0.8 (2.8) 1.7 (5.9)
SIP68 7.7 (10.9) 5.8 (6.7) 4.3 (10.3) 4.5 (10.1) 6.1 (12.0)
Inpatient SA 1.4 (4.1) 1.2 (2.6) 0.7 (2.5) 0.8 (2.4) 0.7 (2.8)
MC 9.7 (14.2) 8.3 (11.8) 7.8 (16.1) 5.8 (14.0) 5.3 (14.1)
PAC 13.7 (23.3) 12.7 (23.7) 12.3 (25.0) 14.8 (16.9) 6.5 (18.3)
SB 23.7 (24.3) 25.0 (21.2) 18.6 (26.4) 10.7 (19.5) 9.6 (13.3)
ES 21.8 (28.1) 23.3 (19.0) 15.4 (29.2) 11.9 (25.5) 6.8 (17.0)
MR 7.1 (13.9) 32.0 (39.6) 5.5 (12.1) 3.7 (9.9) 2.3 (7.1)
SIP68 12.9 (12.4) 17.1 (11.3) 10.1 (14.7) 8.0 (12.3) 5.2 (8.6)
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short contact treatment. Although HRQoL was
impaired more in inpatient treatment, and it did not
lead to a significant improvement in HRQoL at the end
of treatment, the actual gain in HRQoL was comparable
for any of the three treatment modalities at 3 months’
follow-up.
DISCUSSION
In our study short contact dithranol treatment, UVB
phototherapy and inpatient dithranol treatment all led
to an improvement in HRQoL, although at different
time intervals following therapy. Improvement in
HRQoL following different local, systemic, combined
or inpatient treatments has been reported in many other
studies (7, 25, 26). Inpatients are known to score worse
on HRQoL instruments, reporting more anxiety and
depression, an impaired ability to express anger, and
having worse scores for irritability and aggression (27,
28). Inpatient treatment in this study also led to worse
HRQoL scores than the other two treatment modalities;
although inpatient treatment resulted in a higher clinical
response rate (Fig. 1) and the treatment time was
shorter, there was no improvement in HRQoL at the
end of treatment. Only after 3 months of follow-up the
HRQoL of inpatients showed significant improvement.
The worse HRQoL score at the end of treatment is
thought to be partly due to clinical treatment itself, as
this substantially impairs a person’s social and leisure
time activities. The fact that inpatients showed higher
impairment in the sub-domains Social Behaviour and
Motor Range supports the assumption that inpatients
are substantially disabled because of hospitalization.
This assumption may also explain why the HRQoL
scores improved during the follow-up. It reflects the
improved appraisal of HRQoL due to the return of the
patient to their normal social surroundings. A signifi-
cant improvement in Emotional Stability following
treatment was only observed after short contact treat-
ment. Probably this is a direct consequence of the care
instruction programme used, which gives the patient a
feeling of control over the disease and consequently
might positively affect their emotional stability.
The individual perception of living with psoriasis
varies considerably. A correlation between the PDI and
the SIP on one hand and the clinical severity of the
psoriasis on the other hand was hardly ever found in
other studies (28). We observed such a correlation only
once, at 3 months’ follow-up in the inpatient group. A
possible explanation might be that following inpatient
treatment, the remission period was shorter compared
with the other two treatment modalities. The (rather
rapidly) recurring psoriatic lesions might negatively
influence a patient’s emotional and behavioural reaction
to these recurring lesions, and consequently yield worse
HRQoL scores.
Developed as a general measure of health and focused
primarily on performance- and activity-based dimen-
sions, the SIP68 was not expected to score high in
patients with psoriasis, who in general are healthy and
active (7). Although the original SIP has been used
successfully in psoriasis studies (7, 11), the SIP68 was
never used in this field before. Studies using the SIP68 in
other patient populations can be used as an indicative
point of reference. Our patients with psoriasis experi-
enced impairment comparable to patients suffering from
Crohn’s disease (SIP68 5 8.7), ankolysing spondylitis
(SIP68 5 13.7) or patients with back and neck com-
plaints (SIP68 5 7.6). They experienced far less
impairment in general HRQoL compared with patients
with a spinal lesion (SIP68 5 29.6) or with cancer
(SIP68 5 16.9) (29). The PDI scores we found are
Fig. 2. (a) Mean SIP68 scores (SEM) and (b) mean PDI score (SEM) of short contact treatment (SCT), UVB phototherapy (UVB) and inpatient
treatment (Inpat) at the four measurements, with the number of patients who completed the instrument.
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consistent with PDI scores reported in other studies on
HRQoL in psoriasis patients (11, 12, 23, 30, 31).
The fact that at the start of treatment inpatients
already scored higher on both HRQoL instruments
compared with patients treated with short contact
treatment or UVB might be interpreted as a drawback
of this study. A possible cause could have been the
randomization procedure that might have partially led
to a selection bias. This is possibly also mirrored in
the (not significant) higher PASI and area% scores
of inpatients at the baseline measurement. The three
parallel randomization strata were chosen because of the
clinical set-up of this study (e.g. treatments were too
different to offer them to everybody). If we had not
conducted the study in this way, we would never have
been able to include a substantial number of patients.
The higher scores in the inpatient group might also
be attributed to a difference in patients’ perceptions of
their disease. Patients who experience their psoriasis as
very severe and disabling, will probably have less
problems with inpatient treatment than patients who
are less disabled by their psoriasis. Consequently, the
knowledge that treatment was going to be provided
clinically might have meant that these patients went on
to experience their psoriasis as more impairing. Psoriasis
can be rather therapy-resistant. We did not incorporate
previously given therapies and therapy results in the
analysis of this study. It might be useful in following
studies to do so.
Although the gain in HRQoL at 3 months’ follow-up
in any of the three treatment modalities was equal,
inpatient treatment induced a smaller improvement of
HRQoL scores than short contact treatment or UVB up
to 3 months’ follow-up. However, the clinical scores
were best for inpatient treatment, with only 5 of
60 patients (8.3%) with a therapy failure compared with
35 of 100 patients (35%) treated with short contact
treatment and 30 of 78 (38.5%) patients treated with
UVB. Still, when comparing HRQoL following short
contact treatment with HRQoL following inpatient
treatment, short contact treatment deserves preference.
In conclusion, HRQoL measurements in psoriasis
patients show differences between treatments but do not
seem to be suitable to replace clinical outcome measures.
They certainly are an advantageous additive measure
besides clinical outcome measures, as they show what a
treatment comprises for the patient. When choosing
a suitable psoriasis treatment that matches with the
individual needs of the patient, HRQoL data can help
the clinician in making a choice.
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